Alzheimer Disease/Dementia

Higher levels of cardiovascular health were associated with lower levels of neurofilament light chain across age, sex, race/ethnicity, and Alzheimer disease risk.

Analysis of data from the donanemab TRAILBLAZER development program underscores the essential role of patient selection and treatment monitoring.

Axsome Therapeutics reported that the FDA feedback supports the company's regulatory package for a sNDA for the dextromethorphan/bupropion combination.

The proprietary combination of 2 neurostimulation modalities deployed simultaneously may enhance efficacy while reducing treatment time by 70%, the company said.

Phospho-tau serine-262 and serine-356 were identified as biomarkers for early Alzheimer disease detection in a new study published in Nature Medicine.

Your daily dose of the clinical news you may have missed.

Your daily dose of the clinical news you may have missed.

Agitation is the most common disabling neuropsychiatric symptom experienced by individuals with Alzheimer dementia; Grossberg explains how common in this short interview.

Your daily dose of the clinical news you may have missed.

Your daily dose of the clinical news you may have missed.

Dr Turner reviews the profile of the individual who is most likely to benefit from lecanemab therapy.

Georgetown University memory disorders expert R Scott Turner, PhD, MD, reviews the science behind approval of lecanemab for monthly maintenance dosing of lecanemab.

Once every four weeks maintenance dosing of lecanemab may be easier for patients and care partners to continue treatment.

When a patient with Alzheimer dementia becomes agitated, check the physical environment for a trigger before pulling the trigger on a medication, dementia expert George Grossberg, MD, recommends.

The revolutionary medications are the first new treatments for Alzheimer disease to be approved in more than 20 years and the first-ever disease-modifying drugs.

Your daily dose of the clinical news you may have missed.

Levels of acetyl-L-carnitine and free carnitine correlated significantly with disease severity, particularly in women with moderate and severe Alzheimer dementia.

Vesper Bio anticipates completing enrollment and dosing by mid-2025 in the Phase 1B/2A trial for VES001.

A geriatric psychiatrist talks about the importance of asking caregivers about behavior in order to understand and treat agitation in Alzheimer dementia.

The effective approach to identifying risk for the disruptive cognitive issues holds promise for development of early intervention to mitigate decline.

The Florey Dementia Index showed robustness across different cohorts but more testing is needed, researchers reported.

Agitation in Alzheimer disease is not limited to the later stages, geriatric psychiatrist George Grossberg, MD, explains; look for it across the spectrum.

Annual incidence of dementia will double in White adults and triple among Black adults. The updated estimates place the lifetime risk of developing dementia after age 55 at 42%.

The geriatric psychiatrist refers in this interview to agitation in Alzheimer disease, a significant neuropsychiatric symptom that should not be dismissed.